Bicycle Therapeutics PLC (BCYC): R&D Expense
$240.28M
Year ended 2025-12-31
$200.26M
Trailing 12 months to 2026-06-30
+43.3%
3-year compound annual growth
+48.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $240.28M | +38.9% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $172.97M | +10.5% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $156.50M | +91.8% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $81.61M | +81.8% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $44.88M | +35.4% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $33.15M | +29.8% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $25.54M | +23.0% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $20.76M | +75.0% | 2021-03-11, From 2018-01-01 |
| 2017-12-31 | $11.87M | n/a | 2020-03-10, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
Compare BCYC, ASMB, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗